Article Sidebar

Submitted
Sep 21, 2022
Published
Jan 31, 2023
Download
Pdf
Statistic
Read Counter : 425 Download : 461

Downloads

Download data is not yet available.

Main Article Content

Abstract

Late antiviral treatment can potentially cause the Covid-19 virus to replicate very quickly, so it is necessary to understand antiviral drugs and optimize treatment for Covid-19 patients. The study aimed to determine the correlation between the severity, speed of administration of antivirals, and the recovery time of Covid-19 patients. This type of research is an observational study with retrospective data collection on 94 Covid-19 medical records at “X” Hospital Cirebon from 316 populations in June-July 2021 according to inclusion criteria. The data analysis used was univariate and bivariate using Spearman's Rho. The 55–59-year age group (28.7%) was the most infected with Covid-19. There are more males than females (52.1% vs 47.9%). Favipiravir therapy (43.6%) was given the most. Moderate severity (74.5%) had the highest proportion. The speed of administration of antivirals was most initiated at 5-8 days (42.6%) after the onset of symptoms. The maximum recovery time for Covid-19 patients is 13-18 days (58.5%). A strong positive correlation between the speed of giving antivirals to the recovery time of Covid-19 patients (sig. 0.000) and the correlation coefficient of 0.659. Does not show a correlation between the severity of recovery time (sig. 0.113) and speed of antiviral administration to the severity of Covid-19 patients (sig. 0.297). There is a correlation between the early antiviral treatment and the recovery time of Covid-19 patients; the earlier antiviral therapy is given, the faster it will heal.

Keywords

Covid-19 Early antiviral treatment Severity Duration of recovery

Article Details

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

References

  1. Amalia, L., Irwan, I., & Hiola, F. (2020). Analisis Gejala Klinis Dan Peningkatan Kekebalan Tubuh Untuk Mencegah Penyakit Covid-19. Jambura Journal of Health Sciences and Research, 2(2), 71–76. https://doi.org/10.35971/jjhsr.v2i2.6134
  2. Beigel, J. H., Tomashek, K. M., Dodd, L. E., Mehta, A. K., Zingman, B. S., Kalil, A. C., Hohmann, E., Chu, H. Y., Luetkemeyer, A., Kline, S., Lopez de Castilla, D., Finberg, R. W., Dierberg, K., Tapson, V., Hsieh, L., Patterson, T. F., Paredes, R., Sweene, H. C. (2020). Remdesivir for the Treatment of Covid-19 — Final Report. New England Journal of Medicine, 383(19), 1813–1826. https://doi.org/https://doi.org/10.1056/nejmoa2007764
  3. Bulut, C., & Kato, Y. (2020). Epidemiology of covid-19. Turkish Journal of Medical Sciences, 50(SI-1), 563–570. https://doi.org/10.3906/sag-2004-172
  4. Chron, A., Ny, P., Kelsom, C., Nieberg, P., Shriner, K., & Wong-Beringer, A. (2020). Shorter time from symptom onset to hospitalization si associated with worse outcomes in patients with COVID-19. ESCMID Conference on Coronavirus Disease, 331.
  5. Fadilah, S. (2018). Kesetaraan Gender : Fenomena Pergeseran Peran Ekonomi Wanita Dari Tulang Rusuk Menjadi Tulang Punggung. Mitra Gender (Jurnal Gender Dan Anak, 18–26.
  6. Mukherjee, S., & Pahan, K. (2021). Is COVID-19 Gender-sensitive? Journal of Neuroimmune Pharmacology, 16(1), 38–47. https://doi.org/10.1007/s11481-020-09974-z
  7. NIH. (2021). Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19). In Nih (Vol. 2019). National Institutes of Health.
  8. PDPI, PERKI, PAPDI, PERDATIN, & IDAI. (2020). Pedoman tatalaksana COVID-19 Edisi 3 Desember 2020. In Pedoman Tatalaksana COVID-19.
  9. Peng, F., Tu, L., Yang, Y., Hu, P., Sun, J., Xu, G., & Chang, C. (2020). Management and Treatment of COVID-19 : The Chinese Experience. Canadian Journal of Cardiology, 36(6), 915–930. https://doi.org/10.1016/j.cjca.2020.04.010
  10. Popov, G. T., Baymakova, M., Vaseva, V., Kundurzhiev, T., & Mutafchiyski, V. (2020). Clinical Characteristics of Hospitalized Patients with COVID-19 in Sofia, Bulgaria. Vector-Borne and Zoonotic Diseases, 20(12), 910–915. https://doi.org/https://doi.org/10.1089/vbz.2020.2679.
  11. Riadi, E. (2016). Statistika Penelitian (Analisis Manual dan IBM SPSS) (T. A. Prabawati (ed.). In Penerbit CV.ANDI OFFSET.
  12. Satgas Covid-19. (2021). Analisis Data Covid-19 Indonesia Update Per 13 Juni 2021. Www.Covid19.Go.Id.
  13. WHO. (2020). Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19). In The WHO-China Joint Mission on Coronavirus Disease 2019 (Vol. 1, Issues 16-24 February).
  14. Wu, J., Li, W., Shi, X., Chen, Z., Jiang, B., Liu, J., Wang, D., Liu, C., Meng, Y., Cui, L., Yu, J., Cao, H., & Li, L. (2020). Early antiviral treatment contributes to alleviate the severity and improve the prognosis of patients with novel coronavirus disease (COVID-19). Journal of Internal Medicine, 288(1), 128–138. https://doi.org/10.1111/joim.13063
  15. Xu, K., Cai, H., Shen, Y., Ni, Q., Chen, Y., Hu, S., Li, J., Wang, H., Yu, L., Huang, H., Qiu, Y., Wei, G., Fang, Q., Zhou, J., Sheng, J., Liang, T., & Li, L. (2020). Management of COVID-19: the Zhejiang experience. Zhejiang Da Xue Xue Bao. Yi Xue Ban = Journal of Zhejiang University. Medical Sciences, 49(2), 147–157. https://doi.org/10.3785/j.issn.1008-9292.2020.02.02